John Brock Harris1,2, Amy P Holmes3. 1. Wingate University School of Pharmacy (JBH), Wingate University, Wingate, NC. 2. Novant Health Hemby Children's Hospital (JBH), Charlotte, NC. 3. Brenner Children's Hospital (APH), Wake Forest Baptist Medical Center, Winston-Salem, NC.
Abstract
OBJECTIVE: The incidence of neonatal abstinence syndrome (NAS) has increased in recent years. Treatment approaches usually involve opioid replacement; however, the optimal treatment strategy is unknown. This study sought to determine the impact of weight- and symptom-based morphine dosing strategies on LOS and medication exposure in patients with NAS. METHODS: A retrospective review was conducted from May 2015 to June 2017 at 2 NICUs within a health-system using different dosing approaches for NAS. Data were compared using Fisher exact tests for categorical data and t tests and Wilcoxon ranked sums for continuous data. RESULTS: Baseline demographics were well-matched except for postmenstrual age at morphine initiation (p = 0.04). The weight-based group had a larger initial morphine dose (p < 0.001) and fewer number of steps to maximum morphine dose (p = 0.009). There were no differences between groups in LOS, number of dose adjustments, doses administered, weaning steps, maximum dose, or need to re-escalate dosing. There was also no difference between the first 3 modified Finnegan scores (MFS) after transferring patients to a neonatology service. Neonates with symptom-based dosing had a higher maximum MFS (p = 0.024). Neonates in the symptom-based group required adjunct therapy more often (p < 0.0001). CONCLUSIONS: Data indicate the dosing strategy impacts number of steps to reach maximum dose and need for adjunctive therapy. Weight-based dosing may decrease the number of steps required to reach the morphine maximum dose and the need for adjunctive therapy by controlling NAS symptoms earlier. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2022.
OBJECTIVE: The incidence of neonatal abstinence syndrome (NAS) has increased in recent years. Treatment approaches usually involve opioid replacement; however, the optimal treatment strategy is unknown. This study sought to determine the impact of weight- and symptom-based morphine dosing strategies on LOS and medication exposure in patients with NAS. METHODS: A retrospective review was conducted from May 2015 to June 2017 at 2 NICUs within a health-system using different dosing approaches for NAS. Data were compared using Fisher exact tests for categorical data and t tests and Wilcoxon ranked sums for continuous data. RESULTS: Baseline demographics were well-matched except for postmenstrual age at morphine initiation (p = 0.04). The weight-based group had a larger initial morphine dose (p < 0.001) and fewer number of steps to maximum morphine dose (p = 0.009). There were no differences between groups in LOS, number of dose adjustments, doses administered, weaning steps, maximum dose, or need to re-escalate dosing. There was also no difference between the first 3 modified Finnegan scores (MFS) after transferring patients to a neonatology service. Neonates with symptom-based dosing had a higher maximum MFS (p = 0.024). Neonates in the symptom-based group required adjunct therapy more often (p < 0.0001). CONCLUSIONS: Data indicate the dosing strategy impacts number of steps to reach maximum dose and need for adjunctive therapy. Weight-based dosing may decrease the number of steps required to reach the morphine maximum dose and the need for adjunctive therapy by controlling NAS symptoms earlier. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2022.
Authors: Jessica N Snowden; A Akshatha; Robert D Annett; Margaret M Crawford; Abhik Das; Lori A Devlin; Rosemary D Higgins; Zhuopei Hu; Elizabeth Lindsay; Stephanie Merhar; Clare Campbell Nesmith; Heather Pratt-Chavez; Judith Ross; Alan E Simon; M Cody Smith; Christine B Turley; Anita Walden; Leslie Young; Bonny Whalen Journal: Hosp Pediatr Date: 2019-07-19
Authors: Wendy Timpson; Cheryl Killoran; Louise Maranda; Alan Picarillo; Elisabeth Bloch-Salisbury Journal: Adv Neonatal Care Date: 2018-02 Impact factor: 1.968
Authors: Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer Journal: N Engl J Med Date: 2010-12-09 Impact factor: 91.245
Authors: Veeral N Tolia; Stephen W Patrick; Monica M Bennett; Karna Murthy; John Sousa; P Brian Smith; Reese H Clark; Alan R Spitzer Journal: N Engl J Med Date: 2015-04-26 Impact factor: 91.245
Authors: Stephanie L Merhar; Songthip Ounpraseuth; Lori A Devlin; Brenda B Poindexter; Leslie W Young; Sean D Berkey; Moira Crowley; Adam J Czynski; Autumn S Kiefer; Bonny L Whalen; Abhik Das; Janell F Fuller; Rosemary D Higgins; Vaishali Thombre; Barry M Lester; P Brian Smith; Sarah Newman; Pablo J Sánchez; M Cody Smith; Alan E Simon Journal: Pediatrics Date: 2021-03 Impact factor: 7.124